Bibliographic Details
| Title: |
DNA methylation trajectories and accelerated epigenetic aging in incident type 2 diabetes. |
| Authors: |
Fraszczyk, Eliza, Thio, Chris H. L., Wackers, Paul, Dollé, Martijn E. T., Bloks, Vincent W., Hodemaekers, Hennie, Picavet, H. Susan, Stynenbosch, Marjolein, Verschuren, W. M. Monique, Snieder, Harold, Spijkerman, Annemieke M. W., Luijten, Mirjam |
| Source: |
GeroScience; Dec2022, Vol. 44 Issue 6, p2671-2684, 14p |
| Subject Terms: |
TYPE 2 diabetes, DNA methylation, EPIGENETICS, AGING, BIOMARKERS |
| Abstract: |
DNA methylation (DNAm) patterns across the genome changes during aging and development of complex diseases including type 2 diabetes (T2D). Our study aimed to estimate DNAm trajectories of CpG sites associated with T2D, epigenetic age (DNAmAge), and age acceleration based on four epigenetic clocks (GrimAge, Hannum, Horvath, phenoAge) in the period 10 years prior to and up to T2D onset. In this nested case–control study within Doetinchem Cohort Study, we included 132 incident T2D cases and 132 age- and sex-matched controls. DNAm was measured in blood using the Illumina Infinium Methylation EPIC array. From 107 CpG sites associated with T2D, 10 CpG sites (9%) showed different slopes of DNAm trajectories over time (p < 0.05) and an additional 8 CpG sites (8%) showed significant differences in DNAm levels (at least 1%, p-value per time point < 0.05) at all three time points with nearly parallel trajectories between incident T2D cases and controls. In controls, age acceleration levels were negative (slower epigenetic aging), while in incident T2D cases, levels were positive, suggesting accelerated aging in the case group. We showed that DNAm levels at specific CpG sites, up to 10 years before T2D onset, are different between incident T2D cases and healthy controls and distinct patterns of clinical traits over time may have an impact on those DNAm profiles. Up to 10 years before T2D diagnosis, cases manifested accelerated epigenetic aging. Markers of biological aging including age acceleration estimates based on Horvath need further investigation to assess their utility for predicting age-related diseases including T2D. [ABSTRACT FROM AUTHOR] |
|
Copyright of GeroScience is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
